Noninterventional Study of Safety, Efficacy, Adherence, and Health Related Quality of Life in Patients Receiving a Once Daily Single Tablet Regimen for HIV 1 Infection in Germany STR-NIS – (STRike)

Noninterventional Study of Safety, Efficacy, Adherence, and Health Related Quality of Life in Patients Receiving a Once Daily Single Tablet Regimen for HIV 1 Infection in Germany STR-NIS – (STRike) - STRike

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000722

Enrollment

800

Registered

2011-02-25

Start date

2011-03-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B24

Interventions

Group 1: Observational group 1: Atripla use started 12-24 months prior to enrollment Group 2: Observational group 2: Atripla use starting with enrollment, SF 36 questionnaire at Enrollment, and approx

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Arm 1 and 2: Adults with HIV-1-infection, who are with their current antiretroviral combination therapy virologically suppressed (HIV-1-RNA < 50 copies/ml) for at least three months. Arm 3: Antiretroviral naive adults with HIV-1-infection and viral load of <= 100.000 copies HIV-1-RNA/ml arm 4 - Adults with HIV-1 infection, who are antroretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild

Exclusion criteria

Exclusion criteria: Patients not fulfilling the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Viral load (HIV RNA) at month 24	—

Secondary

Measure	Time frame
SF 36 Quality of life (change from Baseline, each visit)	—

Countries

Germany

Contacts

Public ContactMarion Heinzkill

Gilead Sciences GmbH

marion.heinzkill@gilead.com089 89 98 90 173

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026